Erythrotelangiectasia rosacea
Conditions
Interventions
half dose abrocitinib:Take one tablet of Abu Xitinib orally once a day for 4 weeks of treatment
pimcrolimus:Topical application of pimecrolimus once daily on the face for 4 weeks
full dose abrocitinib:Take Abuxitinib orally twice a day, one tablet each time, and treat for 4 weeks
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Women aged 18-60 with no cognitive impairment; 2) Rosacea with erythema telangiectasia that does not respond to traditional treatment (oral melamycin, topical tacrolimus) or relapsing; 3) After fully explaining the purpose and content of the clinical trial (including the subject's compliance, etc.), on the basis of full understanding, voluntarily sign the informed consent to participate in the clinical trial.
Exclusion criteria
Exclusion criteria: 1) Known allergy to the experimental drug or related drugs; 2) Received rosacea treatment (antibiotics, phototherapy, etc.) within 3 months before enrollment; 3) Patients with facial concomitations with other diseases that may affect the evaluation of efficacy (skin photosensitivity, porphyria, others) Photodermatosis, etc.); 4) Participate in any drug clinical trial (as a subject) within 1 month before participating in this trial; 5) Complicated with serious diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hyperemia Press and wait; 6) Patients with abnormal liver function, dyslipidemia or severe hypoimmunity; 7) Pregnant or lactating women, and participants of reproductive age (including men) who refused to use appropriate contraception during the study period; 8) Have a serious physical or mental illness that the investigator believes may affect treatment, evaluation, or protocol of the study Subjects with poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy propotion (erythema area); | — |
Secondary
| Measure | Time frame |
|---|---|
| a* value;erythema index;investigator global index;skin barrier function score; | — |
Countries
China
Contacts
Public ContactXia Li
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed